<DOC>
	<DOCNO>NCT00193531</DOCNO>
	<brief_summary>carboplatin etoposide , follow maintenance therapy weekly paclitaxel patient poorly differentiate neuroendocrine carcinoma . We hope identify `` standard treatment '' unusual group patient usually eligible clinical trial .</brief_summary>
	<brief_title>Paclitaxel , Carboplatin , Oral Etoposide Followed Weekly Paclitaxel High Grade Neuroendocrine Carcinoma</brief_title>
	<detailed_description>Upon determination eligibility , patient receive : - Paclitaxel + Carboplatin + Etoposide</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Neuroendocrine</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>To include study , must meet following criterion : Metastatic poorly differentiate neuroendocrine carcinoma Unknown primary site Able perform activity daily live minimal assistance Measurable evaluable disease Adequate bone marrow , liver function kidney function No previous treatment chemotherapy Understand nature study give write informed consent . You participate study follow apply : Age &lt; 18 year Previous malignancy within five year Women pregnant lactate Recent history cardiovascular disease Meningeal metastases Please note : There additional inclusion/exclusion criterion . The study center determine meet criterion . If qualify trial , study personnel explain reason . If qualify , study personnel explain trial detail answer question may .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2008</verification_date>
</DOC>